MedAdvisor Limited (AU:AHE)
ASX:AHE
Want to see AU:AHE full AI Analyst Report?
AHE Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.17
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.73M
Market Cap
AU$12.12M
Enterprise ValueAU$15.78M
Total Cash (Recent Filing)AU$10.30M
Total Debt (Recent Filing)AU$17.40M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding637,676,800
10 Day Avg. Volume474,818
30 Day Avg. Volume1,728,714
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)11.59
Price to Sales (P/S)0.19
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$110.67M
Bulls Say, Bears Say
Bulls Say
Platform-led Business ModelMedAdvisor’s platform ties pharmacy workflow, patient adherence tools and brand channels into a single product stack. That integration creates durable customer stickiness and operational embedment in pharmacy workflows, supporting recurring usage and long-term contract retention.
Dual Revenue StreamsRevenue comes from both pharmacy subscriptions/services and life-sciences brand programs, reducing single-customer concentration. This structural diversification lets the company monetize both recurring software fees and program-based marketing spend, supporting resilience across cycles.
Improving Free Cash FlowAn 18.49% rise in free cash flow growth signals improving cash generation versus prior periods. If sustained, this trend can extend runway, fund product development or sales initiatives, and reduce external funding needs even with operating cash flow challenges.
Bears Say
Steep Revenue DeclineA near-40% revenue drop materially weakens scale economics that underpin platform value to pharmacies and brands. Reduced volume erodes capacity to cross-sell and undermines unit economics, constraining margin recovery and investment ability over the next several quarters.
Deep Operating LossesVery large operating losses indicate current business economics don't cover fixed costs, forcing reliance on cash reserves or financing. Persistent negative margins limit reinvestment, jeopardize long-term platform improvements, and increase execution risk without structural cost or revenue fixes.
Weak Balance Sheet / Negative EquityNegative equity and a distorted debt-to-equity ratio signal solvency strain and constrain financing options. This structural weakness raises the cost of capital, limits strategic flexibility for partnerships or M&A, and heightens risk if cash generation doesn't continue improving.
MedAdvisor Limited News
AHE FAQ
What was MedAdvisor Limited’s price range in the past 12 months?
MedAdvisor Limited lowest share price was AU$0.02 and its highest was AU$0.17 in the past 12 months.
What is MedAdvisor Limited’s market cap?
MedAdvisor Limited’s market cap is AU$12.12M.
When is MedAdvisor Limited’s upcoming earnings report date?
MedAdvisor Limited’s upcoming earnings report date is Aug 27, 2026 which is in 129 days.
How were MedAdvisor Limited’s earnings last quarter?
MedAdvisor Limited released its earnings results on Feb 26, 2026. The company reported AU$0.011 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.011.
Is MedAdvisor Limited overvalued?
According to Wall Street analysts MedAdvisor Limited’s price is currently Undervalued.
Does MedAdvisor Limited pay dividends?
MedAdvisor Limited does not currently pay dividends.
What is MedAdvisor Limited’s EPS estimate?
MedAdvisor Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MedAdvisor Limited have?
MedAdvisor Limited has 637,676,800 shares outstanding.
What happened to MedAdvisor Limited’s price movement after its last earnings report?
MedAdvisor Limited reported an EPS of AU$0.011 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MedAdvisor Limited?
Currently, no hedge funds are holding shares in AU:AHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MedAdvisor Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AHE Sentiment 70%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$64.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.95%
12-Months-Change
Fundamentals
Return on Equity
-137.16%
Trailing 12-Months
Asset Growth
-72.24%
Trailing 12-Months
Company Description
MedAdvisor Limited
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts.
Options Prices
Currently, No data available
---